Healthcare providers’ preferences for pediatric pneumococcal vaccination recommendations in the United States
HCPs' choices indicated a preference for the use of PCV20 in both a clinical setting and in pediatric pneumococcal vaccination recommendations, due to the higher number of serotypes covered by PCV20.
Authors
- Christine Poulos (ORCID: https://orcid.org/0000-0001-7810-3411)
- Jeffrey Vietri (ORCID: https://orcid.org/0000-0002-5610-3098)
- Adriano Arguedas (ORCID: https://orcid.org/0000-0002-1659-8225)
- Liping Huang (ORCID: https://orcid.org/0000-0003-3073-7698)
- Maria J. Tort (ORCID: https://orcid.org/0000-0002-6088-451X)
- Vincenza Snow (ORCID: https://orcid.org/0000-0002-0995-2185)
- Kelley Myers (ORCID: https://orcid.org/0000-0002-0936-5677)
- Anna Pierce (ORCID: https://orcid.org/0000-0002-3918-0091)
- Alejandro Cané (ORCID: https://orcid.org/0000-0003-0778-6862)
- Mark H. Rozenbaum (ORCID: https://orcid.org/0000-0001-6209-4370)
Institutions
- Pfizer (United States) (US)
- Triangle (US)
- ICF International (United States) (US)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1080/14760584.2025.2585808
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00